Genelux (GNLX) Cash from Financing Activities (2022 - 2026)
Genelux (GNLX) recorded quarterly Cash from Financing Activities of $18.5 million in Q1 2026, up 6616.67% quarter-over-quarter from $276000.0 in Q4 2025, and up 93.77% on a YoY basis from $9.6 million in Q1 2025.
Genelux (GNLX) Cash from Financing Activities (2022 - 2026) Analysis & Trends
Genelux's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $18.5 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 93.77% year-over-year to $18.5 million; the TTM figure through Mar 2026 stood at $18.9 million (down 49.54% YoY), while the FY2025 annual figure was $9.9 million, down 65.29% from the prior year.
- Cash from Financing Activities was $18.5 million for Q1 2026 at Genelux, up from $276000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $27.7 million in Q2 2024 to a low of -$130000.0 in Q1 2022.
- Historically, Cash from Financing Activities has averaged $7.8 million across 5 years, with a median of $688000.0 in 2024.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities surged 11361.54% in 2023, then plunged 99.81% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $545000.0 in 2022, then retreated by 26.42% to $401000.0 in 2023, then sank by 77.31% to $91000.0 in 2024, then surged by 203.3% to $276000.0 in 2025, then soared by 6616.67% to $18.5 million in 2026.
- The last three Cash from Financing Activities figures came in at $18.5 million (Q1 2026), $276000.0 (Q4 2025), and $52000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | 18.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.54 Mn |
| Mar 31, 2026 | 18.54 Mn |
| Dec 31, 2025 | 276,000.00 |
| Dec 31, 2025 | 276,000.00 |
| Jun 30, 2025 | 52,000.00 |
| Jun 30, 2025 | 52,000.00 |
| Mar 31, 2025 | 9.57 Mn |
| Mar 31, 2025 | 9.57 Mn |
| Dec 31, 2024 | 91,000.00 |
| Dec 31, 2024 | 91,000.00 |
| Jun 30, 2024 | 27.73 Mn |
| Jun 30, 2024 | 27.73 Mn |
| Mar 31, 2024 | 688,000.00 |
| Mar 31, 2024 | 688,000.00 |
| Dec 31, 2023 | 401,000.00 |
| Dec 31, 2023 | 401,000.00 |
| Sep 30, 2023 | 6.36 Mn |
| Sep 30, 2023 | 6.36 Mn |
| Jun 30, 2023 | 22.62 Mn |
| Jun 30, 2023 | 22.62 Mn |